Olympus Corporation (OCPNF)
| Previous close | 14.04 |
| Open | 13.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 13.90 - 14.00 |
| 52-week range | 12.35 - 18.22 |
| Volume | |
| Avg. volume | 1,990 |
| Market cap | 16.362B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 70.00 |
| EPS (TTM) | 0.20 |
| Earnings date | N/A |
| Forward dividend & yield | 0.24 (1.70%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
Business WireCanon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems
TOKYO, January 15, 2024--Canon Medical Systems Corporation (Canon Medical) and Olympus Corporation (Olympus), today announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasoun
PR NewswireOlympus Corp. of the Americas to Host Panel Discussion on Lung Cancer Screening Guidelines and Eligibility
As part of Lung Cancer Awareness Month, Olympus Corp. of the Americas (OCA) and the American Lung Association are partnering to raise awareness around the importance of early detection and provide a better understanding of eligibility around lung cancer screening guidelines.
PR NewswireOlympus Announces Two New Category I CPT Codes for the iTind Procedure
Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today that the American Medical Association (AMA) will issue two new Category I Current Procedural Terminology (CPT®) codes for the iTind™ procedure, a minimally invasive treatment for men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
